Rezolute, INC 10-Q quarterly reports

Rezolute, Inc. filed its Q3 2026 Form 10-Q, detailing financial performance and operational updates, including the disappointing outcome of its Phase 3 sunRIZE trial for congenital hyperinsulinism.

Rezolute, Inc. reports its Phase 3 sunRIZE trial for congenital hyperinsulinism failed, leading to a workforce reduction and increased net losses, while the upLIFT trial for tumor HI progresses.

Rezolute, Inc. reported increased net losses and cash burn in its latest quarterly filing, while advancing two key Phase 3 clinical trials for its lead therapeutic, ersodetug.

Rezolute Inc. announces its Q3 2025 financial results and provides an update on its clinical development programs for ersodetug and RZ402, focusing on hyperinsulinism treatments.

Rezolute Inc. announces its financial results for the quarter ended December 31, 2024, and provides updates on its Phase 3 clinical trials for ersodetug in congenital and tumor hyperinsulinism.

Rezolute Inc. reports a net loss of $15.4 million for the quarter ended September 30, 2024, while advancing its clinical programs for hyperinsulinism and diabetic macular edema.

Rezolute Inc.'s Q3 2024 report reveals ongoing clinical trial progress, a partial clinical hold on RZ358 in the U.S., and a securities exchange agreement impacting share structure.

Rezolute Inc. reports a net loss of $28.4 million for the six months ended December 31, 2023, while advancing its clinical programs for RZ358 and RZ402.